Inflammatory bowel disease therapy: Current state-of-the-art

Current Opinion in Gastroenterology

Volumn 27, Issue 4, 2011, Pages 346-357

  Blonski, Wojciech ^a,b   Buchner, Anna M ^b   Lichtenstein, Gary R ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

antitumor necrosis factor antibodies; corticosteroids; Crohn's disease; immunomodulators; inflammatory bowel disease; mesalamine; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BALSALAZIDE; BETA1A INTERFERON; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; NATALIZUMAB; OLSALAZINE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE;

ALLERGY; CANCER RISK; COLON RESECTION; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HISTOPLASMOSIS; HUMAN; LEUKOPENIA; LYMPHOMA; NAUSEA; PANCREATITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; REVIEW; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; BUDESONIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES;

EID: 79958776171     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328347aef3     Document Type: Review

References (93)

1. Su C, Lichtenstein G. Ulcerative Colitis. In: Feldman M, Friedman L, Brandt L (editors). Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 8th edition. Philadelphia: Saunders Elsevier; 2006. pp. 2499-2549.
2. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107:3-11. (Pubitemid 24195339)
3. Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001; 15:251-256. (Pubitemid 32142504)
4. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006: CD000543.
5. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006: CD000544.
6. LIALDA [prescribing information] Wayne, PA: Shire Pharmaceuticals Inc; 2009.
7. APRISO [prescribing information] Morrisville, NC: Salix Pharmaceuticals Inc; 2008.
8. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26:205-215. (Pubitemid 46985493)
9. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5:95-102. (Pubitemid 46096842)
10. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75; quiz 432-3.
11. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009; 15:1-8.
12. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57:893-902. (Pubitemid 351919522)
13. Prantera C, Kohn A, Campieri M, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009; 30:908-918.
14. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249-266. (Pubitemid 14218578)
15. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993; 104:1293-1301. (Pubitemid 23235401)
16. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994; 19:278-282.
17. Arber N, Odes HS, Fireman Z, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995; 20:203-206.
18. Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001; 49:552-556. (Pubitemid 32896987)
19. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993; 104:435-439. (Pubitemid 23033415)
20. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology 1992; 103:363-368.
21. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997; 112:1069-1077. (Pubitemid 27157516)
22. Thomson AB, Wright JP, Vatn M, et al. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995; 9:673-683. (Pubitemid 26042105)
23. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005:CD003715.
24. Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992; 37:29-32.
25. Bresci G, Parisi G, Banti S. Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience. Int J Clin Pharmacol Res 1994; 14:133-138.
26. de Franchis R, Omodei P, Ranzi T, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 1997; 11:845-852. (Pubitemid 27445669)
27. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113:1465-1473. (Pubitemid 27461232)
28. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2010; 12:CD008870.
29. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011.
30. Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2011; 1:CD008414.
31. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501-523; quiz 24. Detailed and updated recent guidelines for management of ulcerative colitis issued by the American College of Gastroenterology.
32. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041-1048.
33. Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1:217-222.
34. Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 2:441-443.
35. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255-260. (Pubitemid 32729372)
36. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1959; 1:387-394.
37. Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965; 1:188-189.
38. Powell-Tuck J, Bown RL, Chambers TJ, Lennard-Jones JE. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion 1981; 22:263-270.
39. Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010:CD007698.
40. Lofberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996; 110:1713-1718. (Pubitemid 26169207)
41. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4:28-62.
42. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465-484.
43. Tromm A, Bunganic I, Tomsova E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011; 140:425-434 e1.
44. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008: CD000296.
45. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331:842-845. (Pubitemid 24289711)
46. Rutgeerts P. The use of budesonide in the treatment of active Crohn's disease is good clinical practice. Inflamm Bowel Dis 2001; 7:60-61; discussion 2-3.
47. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:935-939. (Pubitemid 43374542)
48. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4:627-630.
49. Caprilli R, Carratu R, Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis 1975; 20:115-120.
50. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69:96-99.
51. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284:1291-1292. (Pubitemid 12150320)
52. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55:47-53. (Pubitemid 41820634)
53. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35:360-362.
54. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99:1122-1128. (Pubitemid 38917818)
55. Chebli LA, Chaves LD, Pimentel FF, et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2010; 16:613-619.
56. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007:CD000478.
57. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121-1125. (Pubitemid 41025906)
58. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination antitumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7:874-881.
59. Vos AC, Bakkal N, Minnee RC, et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2010. [Epub ahead of print].
60. Kotlyar DS, Gisbert JP, Lewis JD, et al. Overall incidence of hepatosplenic T cell lymphoma in patients with inflammatory bowel disease on thiopurines: a meta-analysis of three population based studies. Abstract accepted for Digestive Disease Week Chicago, Illinois, 2011.
61. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010; 105:1604-1609.
62. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374:1617-1625.
63. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease (IBD): long-term follow-up study of 3900 patients. Gastroenterology 2010; 138:S-671.
64. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130:1047-1053.
65. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:940-987. (Pubitemid 43374543)
66. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713. (Pubitemid 30171620)
67. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010:CD000545.] The most recent meta-analysis of randomized placebo-controlled trials of efficacy and safety of thiopurines in active CD.
68. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009:CD000067.
69. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104:2089-2096.
70. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000: CD000067.
71. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49:656-664. (Pubitemid 32989202)
72. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:36-41e1. Recent comprehensive systematic review of patients with IBD who develop HSTCL.
73. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 3:CD005112.
74. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476. (Pubitemid 41770166)
75. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805-1811. (Pubitemid 40824691)
76. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126:1593-1610. (Pubitemid 38649876)
77. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1-51.
78. Kotlyar DS, Blonski W, Diamond RH, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol 2010; 105:2299-2301.
79. Remicade (Infliximab). Prescribing information. Centocor Ortho Biotech Inc.Malvern, PA. 2009.
80. Humira (Adalimumab). Prescribing Information. Abbott Laboratories, North Chicago, IL. 2010.
81. Cimzia (Certolizumab pegol). Prescribing information. UCB Inc, Smyrna, GA. 2009.
82. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6:644-653. (Pubitemid 351783447)
83. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008: CD006893.
84. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395. Recent SONIC trial comparing combination therapy with azathioprine and infliximab vs. monotherapies with each of these agents alone in patients with CD.
85. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 2003; 98:2372-2382. (Pubitemid 37448744)
86. Natalizumab (Tysabri). Prescribing information. Biogen Idec Inc., Cambridge, MA. 2010.
87. Honey K. The comeback kid: TYSABRI now FDA approved for Crohn disease. J Clin Invest 2008; 118:825-826. (Pubitemid 351364587)
88. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007:CD006097.
89. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925. (Pubitemid 41565956)
90. Blonski W, Lichtenstein GR. Medical treatment of ulcerative colitis. Gastroenterol Pol 2008; 15:359-367.
91. Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflammatory bowel diseases 2004; 10 (Suppl 2):S2-S10. (Pubitemid 39023310)
92. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667. (Pubitemid 351284485)
93. Lin MV, Blonski W, Lichtenstein GR, Present DH. What is the optimal therapy for Crohn's disease: step-up or top-down? Expert Rev Gastroenterol Hepatol 2010; 4:167-180.